Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. - Wikidata - awgldk - TriplyDB

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

http://www.wikidata.org/entity/Q34452272

about

Regulatory factor for X-box family proteins differentially interact with histone deacetylases to repress collagen alpha2(I) gene (COL1A2) expression Clinical use and applications of histone deacetylase inhibitors in multiple myeloma HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases Potential prognostic, diagnostic and therapeutic markers for human gastric cancer New and emerging HDAC inhibitors for cancer treatment Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays Biomarkers of genome instability and cancer epigenetics.Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families.Vitamin D and the epigenome.Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases.A unified 35-gene signature for both subtype classification and survival prediction in diffuse large B-cell lymphomas Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.Histone deacetylases, microRNA and leptin crosstalk in pancreatic cancer.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.Current limitations and future opportunities for epigenetic therapies.Histone deacetylases and cancer.Histone deacetylase 2 is required for chromatin condensation and subsequent enucleation of cultured mouse fetal erythroblasts Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.Multiple susceptibility loci for radiation-induced mammary tumorigenesis in F2[Dahl S x R]-intercross rats.Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?PTIP associated protein 1, PA1, is an independent prognostic factor for lymphnode negative breast cancer.The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer Polyphenols from green tea inhibit the growth of melanoma cells through inhibition of class I histone deacetylases and induction of DNA damage.Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.Potential non-oncological applications of histone deacetylase inhibitors.Gut microbial metabolism and colon cancer: can manipulations of the microbiota be useful in the management of gastrointestinal health?Intracellular signaling and hepatocellular carcinoma.A genomic approach to predict synergistic combinations for breast cancer treatment Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

P2860

Q24289242-61AAA5E6-588E-49A9-8CD3-F08E039DD8A6 Q26745930-9E7FE1C7-5418-455F-BF40-6EEF216FA24B Q26766640-F55EBFC3-8511-4A26-A220-64B491F9A243 Q26866200-E7167E57-6DE5-4D7D-8E5E-1425FF46330D Q27022413-DF9005A4-BBB5-4511-AC44-A622123A7C14 Q28082536-0C0392F8-AA3A-45FA-8734-B1FFBE330BEE Q28550025-904A5BDF-0578-4120-93A1-5571CAC8CEBF Q30248745-B0D991FE-9EC4-4388-A855-8503A4CADA7D Q30886620-4BF986F6-07C0-4B2E-B8E2-5F7DA7B709E1 Q33569349-86329531-AD8A-4CAC-AA7D-F59079835573 Q33635942-D7CFFCCD-6094-415A-9715-6C5BBAA10F07 Q33698097-16F261C8-80A4-4436-BA9C-FD7EB7C045FD Q33705588-2101D55C-DADC-48AE-B823-29016455C291 Q33779854-A7E0E432-A48C-4078-B3C9-9322D3E76BBC Q33829390-5E12EACF-D8D1-4C1D-853C-9AEF782BD3F1 Q34171631-A82DE29D-54EC-4560-A9FA-229685B573D8 Q34195077-C829D103-8D04-42A7-B346-1FDC1C3A05E6 Q34298745-790C39DF-C92C-4107-94F3-84D3528905A1 Q34371044-C2735F24-249C-45E7-A323-A14377890650 Q34408058-7D8BC6E0-2FCA-4EC9-9CC9-F7861AC18A50 Q34417159-AF624DC9-8422-4A9E-8DB3-98E99999BE27 Q34591795-EEDEB33C-12B4-4717-BFD5-47A7DFC08AD0 Q34693969-E39E372B-0AAC-4771-9174-2DF7A3DCF08B Q34964940-6958C81E-5FA0-40EA-BD3B-1F79B1510C4C Q35001132-F9BD5EFC-9A4F-442A-A115-7FE3417D059A Q35049096-26CC06AB-663C-4970-89A1-8415F38B2CFA Q35052701-E1D73311-35B4-4472-BD6F-7A53333E9765 Q35079955-0ECA6504-5286-4C6B-A1D2-278EC4ED545E Q35184499-EC5542F4-D6BA-4068-B812-5527BFA2E6E6 Q35402636-D76D10BB-00A0-42F6-A1F1-5674CE7F1D8F Q35485587-31EFE0D8-ED98-440F-809B-4B621AF8A53D Q35544903-86950BE0-BA92-4549-B55E-1C601936B58A Q35586439-C4813F8B-964A-418B-A2EE-14405AAEA1F4 Q35670293-CD6C29CF-A48A-4E08-9C01-27C9C1771E6F Q35821733-E469ADAE-7492-49B5-BE0F-9D45B6A187C5 Q35914300-38B9E043-EEE7-45DC-9EE2-7F88381EEBAA Q35939690-901D535C-6CEF-4BB4-BD64-D0D76A1254C2 Q35975127-A0ACD55C-0F2D-4F34-A82C-2748AB512AC9 Q35998436-FBEF58B2-0C92-4EA8-AB58-0B3028BD1E2C Q36214527-2BFDADE7-990E-4BEA-9664-1DBCE4285D9E

P2860

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

http://www.wikidata.org/entity/Q34452272

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

@ast

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

@en

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

@nl

type

label

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

@ast

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

@en

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

@nl

prefLabel

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

@ast

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

@en

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

@nl

P1433

Q34452272-04EC1BBB-DF50-4FEF-98B9-3E37E70AE44E

P1476

Q34452272-9C763CCA-ED58-4A1F-AB51-DB34C85C3ACD

P2093

Q34452272-01013EF3-843C-4B33-B6BB-4FBF723BDA74

Q34452272-23754DF0-92A1-47FA-9338-4A0E61820ED1

Q34452272-54C6553A-1F44-4026-A86D-80EB36E5F412

Q34452272-60929E24-1AA3-4BC9-84B9-0AE3C175593D

Q34452272-7573A871-C38B-47F1-8061-68CF4A73C45D

Q34452272-C2BF2C1C-7030-4E7A-882C-5B9F8A53C066

Q34452272-C9E85605-93AE-4D06-8863-6653AE41BA6C

Q34452272-DAFF714D-55FE-4F8C-8FD4-22DC40D6310C

Q34452272-E8C81287-0823-4B1F-B7DA-35D81A35CF67

Q34452272-EE6961C9-911E-4F97-916C-1698AB0498FC

P2860

Q34452272-799F3E7B-2BCA-4923-8361-72459C7A61CE

Q34452272-DF249F7C-614D-4DC0-899F-AFE3B060FE8E

Q34452272-F0E4B471-FB29-42A3-B067-64713689606D

P2888

Q34452272-141A6D8F-8203-4EAC-877C-AB927F5A179B

P304

Q34452272-D8E2B568-7236-48A9-B5E2-66C9C92BC695

P31

Q34452272-653E5DBA-281A-4321-90BB-9ACB05B3542F

P356

Q34452272-3F3690BB-3D5C-4BFD-830D-269615C8E545

P407

Q34452272-E66672D4-8EDF-42DE-B85C-EACD0CCF4543

P433

Q34452272-4675386F-EB1A-4878-B7EC-92FF4BEA53E9

P478

Q34452272-0CA2FDC9-107F-40BF-A3EA-68C49D98BDBE

P577

Q34452272-20A3DD6A-E145-4C58-9558-4E45DCC7DC77

P6179

Q34452272-B3FC7925-B64B-4B06-8E65-D38CAB89EB3A

P698

Q34452272-DF8C586E-9DF8-427F-984C-24E7F4A14928

P356

S10549-005-6001-1

P1433

Breast Cancer Research and Treatment

P1476

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

@en

P2093

Hiroko Yamashita

http://www.w3.org/2001/XMLSchema#string

Hiroshi Sugiura

http://www.w3.org/2001/XMLSchema#string

Hirotaka Iwase

http://www.w3.org/2001/XMLSchema#string

Keiko Mita

http://www.w3.org/2001/XMLSchema#string

Maho Hamaguchi

http://www.w3.org/2001/XMLSchema#string

Shunzo Kobayashi

http://www.w3.org/2001/XMLSchema#string

Tatsuya Toyama

http://www.w3.org/2001/XMLSchema#string

Yasuo Hara

http://www.w3.org/2001/XMLSchema#string

Yoshiaki Ando

http://www.w3.org/2001/XMLSchema#string

Zhenhuan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

RPD3 encodes a second factor required to achieve maximum positive and negative transcriptional states in Saccharomyces cerevisiae.

Inhibitors of aromatase prevent degradation of the enzyme in cultured human tumour cells.

Expression profile of histone deacetylase 1 in gastric cancer tissues.

P2888

s10549-005-6001-1

P304

11-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-005-6001-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1035582384

http://www.w3.org/2001/XMLSchema#string

P698

16172792

http://www.w3.org/2001/XMLSchema#string